Status:
COMPLETED
Whole Body MRI for Cancer Surveillance in A-T
Lead Sponsor:
University of Nottingham
Collaborating Sponsors:
Action for A-T
Nottingham University Hospitals NHS Trust
Conditions:
Ataxia Telangiectasia
Eligibility:
All Genders
4-18 years
Brief Summary
Ataxia Telangiectasia (A-T) is an inherited disorder characterised by cerebellar neurodegeneration, immunodeficiency and respiratory disease. People with A-T have abnormal DNA repair and consequently ...
Detailed Description
Ataxia Telangiectasia (A-T) is an autosomal recessive disorder characterised with cerebellar neurodegeneration, immunodeficiency, respiratory disease and cancer susceptibility (22% by age 20). A-T is ...
Eligibility Criteria
Inclusion
- for MRI scan: Confirmed diagnosis of A-T Aged 5 to 18 years Able to undergo MRI scan without sedation or general anaesthetic, after age-appropriate preparation Able to give informed consent (if 16 or older), or have a parent guardian who is able to give informed consent
- for Post-participation interviews or focus group: Participants who underwent the MRI scan Able to give informed consent (if 16 or older), or have a parent guardian who is able to give informed consent Parents / carers of the participants who underwent the MRI scan Participants and / or parents/carers willing to consent
- for Delphi Study: medical professionals who have 3 years post-qualification experience in A-T medical professionals who are currently employed in a clinical area that is related to A-T
Exclusion
- Contra-indication to MRI scan
Key Trial Info
Start Date :
October 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT05252819
Start Date
October 17 2022
End Date
November 30 2023
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nottingham
Nottingham, United Kingdom, NG7 2UH